Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

TOMI Environmental Solutions, Inc. Announces Hire of New Sales Director as it Grows Its Life Science Sector

Posted on: 16 Aug 17

BEVERLY HILLS, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, including SteraMist™, a hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant, announced today that Joe Lyons, a leader in the life science market, will head up its national sales efforts. Lyons, a 30 year veteran in the industry, was an obvious choice for the role as he already had knowledge of the patented SteraMist™ technology which uses Ionized Hydrogen Peroxide (iHP™).

Lyons stated, “I am really looking forward to joining the TOMI team and am very confident that I will easily develop new business in this industry, while also servicing TOMI’s current customer base. Introducing new customers to what is arguably the best disinfecting / decontaminating product on the market today is an exciting opportunity for me.”

Lyons has signed five new companies, representing 24 states, from California to Ohio. These newly acquired opportunities from multiple states demonstrate his ability to grow business quickly. Additional future growth into specific Canadian provinces is planned as TOMI expects to secure required Canadian registrations in November. TOMI has successfully penetrated the Life Science sector both in the U.S. and internationally. Domestically, Pro Ex Services, ARES Scientific, LLC and Best Known Solutions have been selling the technology since 2015.

Dr. Halden Shane, TOMI’s CEO, stated, “With our recently expanded EPA label, the favorable settlement with SixLog to secure more leads in the industry, and the addition of such a seasoned leader in Joe Lyons, we are poised for even greater penetration in the Life Sciences market.”

About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI’s products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.

For additional information, please visit or contact us at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

CONTACT: MEDIA RELATIONS CONTACT Juliana deRosa Executive Administrator jderosa@tomimist.comGlobeNewswire

Last updated on: 17/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.